NasdaqGM - Nasdaq Real Time Price USD

PROCEPT BioRobotics Corporation (PRCT)

Compare
92.70 -0.87 (-0.93%)
At close: November 20 at 4:00 PM EST
92.50 -0.20 (-0.22%)
Pre-Market: 5:06 AM EST
Loading Chart for PRCT
DELL
  • Previous Close 93.57
  • Open 94.00
  • Bid 92.47 x 200
  • Ask 93.13 x 200
  • Day's Range 91.47 - 94.33
  • 52 Week Range 33.45 - 103.81
  • Volume 433,576
  • Avg. Volume 845,585
  • Market Cap (intraday) 5.016B
  • Beta (5Y Monthly) 1.00
  • PE Ratio (TTM) --
  • EPS (TTM) -1.95
  • Earnings Date Oct 28, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 101.00

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

www.procept-biorobotics.com

626

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PRCT

View More

Performance Overview: PRCT

Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PRCT
121.19%
S&P 500
24.05%

1-Year Return

PRCT
180.40%
S&P 500
31.08%

3-Year Return

PRCT
127.88%
S&P 500
25.95%

5-Year Return

PRCT
164.86%
S&P 500
32.06%

Compare To: PRCT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PRCT

View More

Valuation Measures

Annual
As of 11/20/2024
  • Market Cap

    5.02B

  • Enterprise Value

    4.90B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    23.81

  • Price/Book (mrq)

    20.79

  • Enterprise Value/Revenue

    24.52

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -50.07%

  • Return on Assets (ttm)

    -16.73%

  • Return on Equity (ttm)

    -37.02%

  • Revenue (ttm)

    199.84M

  • Net Income Avi to Common (ttm)

    -100.06M

  • Diluted EPS (ttm)

    -1.95

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    196.76M

  • Total Debt/Equity (mrq)

    34.26%

  • Levered Free Cash Flow (ttm)

    -82.85M

Research Analysis: PRCT

View More

Company Insights: PRCT

Research Reports: PRCT

View More

People Also Watch